CTI Biopharma appoints Michael Metzger to board
Mr. Metzger brings extensive experience leading and growing companies in the biopharmaceutical industry over the last 20 years.
Mr. Metzger is currently president and chief operating officer of Syndax Pharmaceuticals, Inc., a publicly traded immuno-oncology biopharmaceutical company.
Mr. Metzger served as president and chief executive officer of Regado Biosciences, Inc., a former publicly traded biotechnology company, from 2013 to 2015, where he oversaw the company's successful merger with Tobira Therapeutics, Inc. in 2015 and acted as an advisor to Tobira during its subsequent sale to Allergan in 2016.
Previously, Mr. Metzger served as executive vice president and chief operating officer at Mersana Therapeutics, a privately held biotechnology company developing novel immunoconjugate therapies for cancer, from 2011 to 2013 and in senior business development positions including leading mergers and acquisitions at Forest Laboratories, Inc. from 2006 to 2011.
Mr. Metzger served as vice president corporate development at Onconova Therapeutics, Inc., from 2001 until 2006, and was a managing director at MESA Partners, Inc., a venture capital firm, from 1997 to 2001.
He holds a B.A. from George Washington University and an M.B.A. in Finance from the New York University Stern School of Business. ■
LATEST MOVES FROM Washington
- Avalara appoints Tony Susak as general manager
- Red Lion Hotels adds two to board
- Expedia appoints Chelsea Clinton to board
- Microsoft adds Reid Hoffman to board
- Banner Corporation appoints Merline Saintil to board
More inside POST
IAG launches new long-haul airline Level Companies